A note on interpretation: a plateau is not automatically a failure of dose
Lall, S., Tung, L
They need more coordination and follow-up
While GLP-1s manage this beautifully, you need to use the time to create lasting insulin sensitivity
doi: 10.1016/j.chom.2014.11.010 31 ChelakkotC.GhimJ.RyuS
Acting as incretin mimetics, they enhance glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and promote satiety, addressing several core abnormalities in T2DM pathophysiology ( Since the approval of exenatide in 2005, the GLP-1 RA class has expanded to include liraglutide, semaglutide, dulaglutide, and lixisenatide, each differing in half-life, route of administration, and molecular structure ( Pancreatic cancer has drawn particular scrutiny due to its high fatality rate and some early observational reports suggesting elevated risk with incretin-based therapies ( Given the expanding use of GLP-1 RAs in populations already at elevated risk for gastrointestinal malignancies, there is a clear need for a comprehensive synthesis of high-quality evidence (Home et al., 2015
